Cohort A (Dose Level 2) Temporarily Closed to Accrual
Cohort A (extremity/body wall) of NRG-DT001, “A Phase IB Trial of Neoadjuvant AMG 232 Concurrent with Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma (STS),” is temporarily closed to accrual effectively immediately because 3 patients have been enrolled, which is the maximum allowed per protocol.
Cohort A of this trial will be temporarily closed for at least 9 weeks until all 3 patients complete the DLT evaluation period. A broadcast with more details regarding reopening will be sent when all 3 patients have completed the DLT evaluation period. We anticipate cohort A to be open again around mid-March 2020.
Note: Cohort B (abdomen/pelvis/retroperitoneum) is still open to accrual to dose level 1. We encourage all investigators to consider this trial for eligible patients.
Please distribute this information to the appropriate personnel.
This message was sent to email@example.com by NRG-Broadcasts@NRGOncology.org
Four Penn Center
1600 JFK Blvd.
, Philadelphia, PA, 19103